Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Bibliographic Details
Main Authors:	Sha-Sha Wang, Fang Wang, Zhen Zeng, Fang Gao, Huan-Huan Liu, Hui-Na Wang, Yi Hu, Hai-Feng Qin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Oncology
Subjects:	RET intergenic fusion pralsetinib lung adenocarcinoma novel intergenic tyrosine kinase inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1113289/full

Internet